Literature DB >> 26036801

Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

Jon A Detterich1, Roberta M Kato2, Miklos Rabai3, Herbert J Meiselman4, Thomas D Coates5, John C Wood6.   

Abstract

Tricuspid regurgitant (TR) jet velocity and its relationship to pulmonary hypertension has been controversial in sickle cell disease (SCD). Plasma free hemoglobin is elevated in SCD patients and acutely impairs systemic vascular reactivity. We postulated that plasma free hemoglobin would be negatively associated with both systemic and pulmonary endothelial function, assessed by flow-mediated dilation (FMD) of the brachial artery and TR jet velocity, respectively. Whole blood viscosity, plasma free hemoglobin, TR jet, and FMD were measured in chronically transfused SCD pre- and posttransfusion (N = 25), in nontransfused SCD (N = 26), and in ethnicity-matched control subjects (N = 10). We found increased TR jet velocity and decreased FMD in nontransfused SCD patients compared with the other 2 groups. TR jet velocity was inversely correlated with FMD. There was a striking nonlinear relationship between plasma free hemoglobin and both TR jet velocity and FMD. A single transfusion in the chronically transfused cohort improved FMD. In our patient sample, TR jet velocity and FMD were most strongly associated with plasma free hemoglobin and transfusion status (transfusions being protective), and thus consistent with the hypothesis that intravascular hemolysis and increased endogenous erythropoiesis damage vascular endothelia.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26036801      PMCID: PMC4528063          DOI: 10.1182/blood-2014-12-614370

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke.

Authors:  Nelson E Lezcano; Nadine Odo; Abdullah Kutlar; Donald Brambilla; Robert J Adams
Journal:  Stroke       Date:  2006-04-20       Impact factor: 7.914

2.  Measurement of whole blood viscosity profiles via an automated viscometer: technical details and clinical relevance.

Authors:  Tamas Alexy; Eszter Pais; Rosalinda B Wenby; William Hogenauer; Kalman Toth; Herbert J Meiselman; Kenneth R Kensey
Journal:  Clin Lab       Date:  2005       Impact factor: 1.138

3.  Methods for measuring plasma hemoglobin in micromolar concentration compared.

Authors:  V F Fairbanks; S C Ziesmer; P C O'Brien
Journal:  Clin Chem       Date:  1992-01       Impact factor: 8.327

4.  Sickle cell anemia a molecular disease.

Authors:  L PAULING; H A ITANO
Journal:  Science       Date:  1949-11-25       Impact factor: 47.728

Review 5.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Authors:  Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

6.  Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin.

Authors:  Peter C Minneci; Katherine J Deans; Huang Zhi; Peter S T Yuen; Robert A Star; Steven M Banks; Alan N Schechter; Charles Natanson; Mark T Gladwin; Steven B Solomon
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

Review 7.  Pain management of sickle cell disease.

Authors:  Samir K Ballas
Journal:  Hematol Oncol Clin North Am       Date:  2005-10       Impact factor: 3.722

8.  Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.

Authors:  D S Celermajer; K E Sorensen; C Bull; J Robinson; J E Deanfield
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

9.  Effects of erythrocyte deformability and aggregation on the cell free layer and apparent viscosity of microscopic blood flows.

Authors:  Junfeng Zhang; Paul C Johnson; Aleksander S Popel
Journal:  Microvasc Res       Date:  2009-02-04       Impact factor: 3.514

10.  Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.

Authors:  Julia E Brittain; Ben Hulkower; Susan K Jones; Dell Strayhorn; Laura De Castro; Marilyn J Telen; Eugene P Orringer; Alan Hinderliter; Kenneth I Ataga
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

View more
  28 in total

Review 1.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

Review 2.  Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Authors:  Victor R Gordeuk; Oswaldo L Castro; Roberto F Machado
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  The heart in sickle cell disease, a model for heart failure with preserved ejection fraction.

Authors:  John C Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-10       Impact factor: 11.205

Review 4.  Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Ian R Hambleton; Gavin Cho
Journal:  Cochrane Database Syst Rev       Date:  2016-05-20

5.  Transient Hypoxia Model Revealed Cerebrovascular Impairment in Anemia Using BOLD MRI and Near-Infrared Spectroscopy.

Authors:  Julie Coloigner; Chau Vu; Matthew Borzage; Adam Bush; Soyoung Choi; Xin Miao; Yaqiong Chai; Cristina Galarza; Natasha Lepore; Benita Tamrazi; Thomas D Coates; John C Wood
Journal:  J Magn Reson Imaging       Date:  2020-07-09       Impact factor: 4.813

6.  Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Vandana Sachdev; Matthew Hsieh; Neal Jeffries; Anna Noreuil; Wen Li; Stanislav Sidenko; Hwaida Hannoush; Emily Limerick; Delon Wilson; John Tisdale; Courtney Fitzhugh
Journal:  Blood Adv       Date:  2019-10-08

Review 7.  Cardiovascular complications in patients with sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

Review 9.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

10.  Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis.

Authors:  Christian A Schaer; Jeremy W Deuel; Daniela Schildknecht; Leila Mahmoudi; Ines Garcia-Rubio; Catherine Owczarek; Stefan Schauer; Reinhard Kissner; Uddyalok Banerjee; Andre F Palmer; Donat R Spahn; David C Irwin; Florence Vallelian; Paul W Buehler; Dominik J Schaer
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.